A Break-Even Year For US FDA Advisory Committees?

 
• By Michael McCaughan

Meetings have continued to be sparse through 2021, but there will end up being nearly as many panels on withdrawing approved uses as on approving new ones.

The ledger of approval vs withdrawal advisory committees will likely be in the black for the year, but it will be close. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers